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Apoptosis 
Abstract 
Mast cells (MCs) are key effector cells in allergic reactions, through the release of a 
wide variety of granule-stored and de novo synthesized inflammatory mediators. The 
MC secretory granules contain exceedingly high levels of serglycin proteoglycan and 
the heparin-binding proteases chymase, tryptase and carboxypeptidase A.  
   In this thesis the contribution of mouse mast cell protease (mMCP)-4, which is 
thought to be the functional homolog to the human chymase, was studied in the context 
of allergic airway inflammation. Using two models of allergic airway inflammation, 
wild-type (WT) and mMCP-4 deficient (mMCP-4
-/-) mice were treated with ovalbumin 
(OVA) or with house dust mite (HDM) extract. We found that the OVA challenged 
mMCP-4
-/- mice displayed increased airway hyperreactivity and lung eosinophilia and 
in the HDM model they displayed increased serum IgE levels. Moreover, the level of 
IL-33, a pro-inflammatory cytokine, was enhanced in the lung tissue in mMCP-4
-/- mice 
compared to WT mice after HDM-treatment.  
The active proteases stored in MC granules have the ability to cleave a number of 
components upon degranulation. We could demonstrate that proteolytic degradation of 
IL-13 by MCs is mediated by a serine protease, dependent on serglycin proteoglycan 
for its storage.  
Permeabilization of lysosomal membranes often leads to apoptosis and the released 
proteases take part in this process, activating pro-apoptotic compounds. We have found 
that  serglycin
-/-  MCs  are  more  resistant  to  apoptosis  induced  by  secretory  granule 
damage. We showed that serglycin
-/- MCs exhibited reduced caspase-3 and protease 
activity in the cytosol compared to WT cells.  
Taken together, the studies in this thesis suggest that MC chymase plays a protective 
role in the development of allergic airway inflammation and this could possibly be 
explained  by  chymases  ability  to  degrade  the  pro-inflammatory  cytokine,  IL-33.  In 
addition,  we  also  suggest  that  serglycin  proteoglycan  and  serglycin-dependent  MC 
proteases  participate  in  IL-13  degradation  as  well  as  in  MC  apoptosis  induced  by 
secretory granule damage. 
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1  Introduction 
1.1  The immune system 
The immune system protects us from potentially hazardous pathogens such as 
bacteria, fungi, viruses and parasites. The immune system is composed of two 
components  i.e.  the  innate  and  adaptive  (acquired)  immunity.  The  innate 
immune system is always active and is often referred to as the first line of host 
defense  that  rapidly  operates  to  eliminate  foreign  intruders.  It  includes 
anatomic barriers such as the skin, tears, saliva and mucosal surfaces as well as 
the  complement  system  and  various leukocytes.  If  innate  immunity  fails  to 
eliminate a pathogen the adaptive immune system is activated. The adaptive 
immune  response  is  specific  towards  one  particular  pathogen,  and  includes 
recognition of foreign molecules by antigen-specific receptors on B- and T-
lymphocytes. After elimination of the foreign intruder some of the antigen-
specific cells persist creating the unique property of immunological memory. 
Even though innate and adaptive immunity often are regarded as two separate 
components of the immune system, they are linked through cytokine secretion 
and cell-to-cell signaling (Crozat et al., 2009).  
1.2  The allergic immune response 
The allergic immune response is a type I hypersensitivity reaction that involves 
the  production  of  immunoglobulin  (Ig)  E  antibodies  toward  an  antigen 
mediated by the adaptive immune system. The reaction is initiated by antigen 
capture and processed  by  antigen-presenting cells  (APCs)  such as dendritic 
cells or macrophages. These cells mature and migrate to the lymph nodes to 
present peptides of the allergen on major histocompatibility complex (MHC) 
class II molecules to antigen-specific naïve CD4+ T lymphocytes, which in 
turn differentiate and become activated T helper type 2 cells (TH2 cells). In   12 
addition to the antigen presentation, other factors such as the cytokine milieu 
and antigen type and dose also influence the differentiation of naïve T cells. 
TH2  cells  produce  the  cytokines  interleukin  (IL)-4  and  IL-13  and  when 
interacting with antigen-specific B cells via MHC class II and co-stimulatory 
molecules they induce proliferation and class switching to IgE production. The 
primary response to an allergen, i.e. the sensitization phase, is summarized in 
figure  1.  The  antigens  triggering  allergic  reactions  are  mostly  innocuous 
environmental substances referred to as allergens.  
 
Figure 1. Mechanism for allergic sensitization and allergen-specific IgE 
production.  
 
IgE production mainly takes place in the draining lymph nodes at the site of 
allergen entry. However, allergic sensitization may also occur in the mucosa of 
the  airways  where  the  produced  IgE  antibodies  diffuse  locally,  enter  the 
lymphatic vessels and can later be found in the blood stream. In the blood, IgE 
can  bind  to  basophils,  a  type  of  circulatory  granulocyte.  The  systemically 
distributed  IgE  subsequently  binds  to  membrane  receptors  expressed  on  a 
tissue  resident  effector  cells,  i.e.  the  mast  cell  (MC).  IgE  binding  to  its 
receptors on the MCs is referred to as MC sensitization and does not produce 
any  symptoms  of  allergy.  Instead,  once  a  MC  is  sensitized  to  an  allergen, 
subsequent exposure to the same allergen mediates activation of the MCs via 
the IgE-receptor and an allergic reaction is initiated (figure 2). The immediate 
allergic  reaction  occurs  within  minutes  after  the  second  encounter  with  the 
allergen and is a result of MC and/or basophil activation and the release of 
inflammatory mediators.   13 
 
 
Figure 2. Immediate allergic reaction in response to subsequent exposure to 
the allergen via the airways. 
1.3  Allergic asthma 
The  prevalence  of  allergic  diseases  has  increased  during  the  past  decades. 
Today, more than one fifth of the population in industrial countries suffers 
from  allergies,  and  allergic  asthma  is  one  of  the  most  common  diseases 
mediated by IgE antibodies. Allergic asthma is a chronic disorder characterized 
by  reversible  airway  obstruction,  airway  hyperresponsiveness,  airway 
inflammation and alterations in the structural cells and tissue of the airway, i.e., 
remodeling (Maddox & Schwartz, 2002). Airway hyperresponsiveness (AHR) 
is  a  key  feature  of  asthma  and  is  thought  to  be  associated  with  airway 
inflammation  and  remodeling  (Cockcroft  &  Davis,  2006).  The  allergic 
inflammation  can  be  divided  into  three  phases:  early-phase  reactions,  late-
phase reactions and chronic allergic inflammation. Secretion of inflammatory 
mediators by activated MCs are involved in the early inflammatory response 
that  occurs  within  minutes  after  allergen  exposure.  This  reaction  mediates 
bronchoconstriction, vasodilation, mucous secretion, and an increased vascular 
permeability.  The  early  reaction  is  often  followed  by  a  late  response  that 
develops after 2 hours, with a peak after 6-9 hours after allergen exposure. This 
phase  is  characterized  by  recruitment  of  other  immune  cells,  in  particular 
eosinophilic granulocytes, to the site of allergen exposure (Galli et al., 2008).   14 
Mediators involved in cell recruitment in the late-phase reaction originate from 
MCs  and  activated  TH2  cells.  Clinical  features  of  these  events  include 
narrowing of the airways and increased mucous secretion. Repeated exposure 
to the allergen may develop into chronic airway inflammation associated with 
remodeling events of the airways. Airway smooth muscle (ASM) hyperplasia 
and hypertrophy are alterations known to contribute to the pathophysiology of 
asthma. It is likely that thickening of the smooth muscle layer is an important 
component of airway AHR. In addition, remodeling events such as thickening 
of the airway wall and other mechanisms may also contribute to AHR and 
asthma (Cockcroft & Davis, 2006). 
 
1.3.1  Cytokines involved in allergy and asthma 
Cytokines  are  a  group  of  soluble  proteins  that  function  as  key  regulatory 
signaling  molecules  in  the  immune  system.  Cytokines  act  by  binding  to 
specific cell surface receptors, thereby regulating gene expression in the target 
cells. Some cytokines are pro-inflammatory (inducing inflammation) whereas 
others  are  anti-inflammatory  (suppressing  inflammation).  Dysregulation  of 
cytokine expression may result in immune disorders. Therefore, the balance of 
effector cytokines associated with TH1/TH2 cells, regulatory T cells (Tregs) and 
other  anti-inflammatory  cytokines  influences  the  onset  of  different  diseases 
(Dinarello, 2000). As previously described, allergic disorders are dominated by 
TH2 cytokines including IL-4, IL-5, and IL-13 to name but a few. IL-4 is a 
multifunctional  cytokine  produced  by  TH2  cells,  MCs,  basophils  and 
eosinophils. IL-4 induce B-cell switching to IgE synthesis, MC development, 
eosinophil  and  basophil  activation  as  well  as  mucous  secretion  (Vercelli, 
2001). It has been suggested that recruitment of eosinophils plays a role in the 
pathological  process  in  asthmatic  airways,  and  IL-5  is  necessary  for  their 
differentiation,  maturation  and  activation  (O'Byrne  et  al.,  2001).  A  central 
player in allergic reactions and asthma is IL-13. Like IL-4, IL-13 is involved in 
B-cell switching to IgE production. Additionally, it has been demonstrated that 
IL-13 can induce smooth muscle cell (SMC) contractility and mucous secretion 
(Wills-Karp, 2004). IL-13 has been shown to be produced by a number of cells 
including  TH2  cells,  MCs,  basophils,  dendritic  cells  and  natural  killer  cells 
(Wills-Karp, 2004). IL-33 is a relatively newly characterized TH2-associated 
cytokine,  which  has  been  shown  to  be  involved  in  the  recruitment  of 
eosinophils, basophils and TH2 cells (Suzukawa et al., 2008; Komai-Koma et 
al., 2007). It can also induce IL-5 and IL-13 production by TH2 cells (Hsu et 
al., 2010) and administration in mice leads to AHR and mucous production 
(Kondo  et  al.,  2008).  IL-33  is  a  pro-inflammatory  cytokine  produced  by  a   15 
variety  of  cells  including  epithelial  cells,  endothelial  cells,  MCs,  SMCs, 
macrophages and dendritic cells (Moussion et al., 2008). MCs can be activated 
by  IL-33,  which  subsequently  causes  production  of  pro-inflammatory 
cytokines including IL-13 (Ho et al., 2007). Basophils can also be activated by 
IL-33 to produce cytokines (Suzukawa et al., 2008).  
1.4  Mast cells 
MCs  are  highly  granulated  cells  found  in  large  numbers  throughout  all 
vascularized  tissue  in  the  body,  especially  in  tissues  close  to  the  exterior 
environment  such  as  the  skin,  airways  and  gastro-intestinal  tract.  MCs  are 
derived from multipotent hematopoietic stem cells that circulate as progenitors 
in the blood and mature when entering the tissue (Kirshenbaum et al., 1991). 
Mature MCs are considered to be long-lived cells and have the potential to 
regenerate  after  a  degranulation  event  (Xiang  et  al.,  2001).  Due  to  their 
strategic distribution and their ability to sense pathogens and danger, MCs can 
rapidly respond to harmful intruders. They are therefore known as one of the 
immune  cells  participating  in  innate  immunity.  However,  MCs  are  mainly 
known  for  their  role  in  allergies.  In  allergic  responses,  MC  activation  is 
mediated  by  allergen-specific  IgE  antibodies  through  FcεRI  receptor  cross-
linking causing a rapid release of the granule-stored mediators. In addition, 
MCs can also be activated by other mechanisms to secrete granule stored as 
well as de novo synthesized mediators. The mechanisms of MC activation as 
well as the granule-stored mediators are described in further detail later in this 
thesis. 
1.5  Mast cell activation 
A key MC feature is their ability to rapidly respond to various stimuli (figure 
3). The different  types of stimuli include binding to specific surface-bound 
receptors on the MC as well as compounds that have the ability to directly 
activate MCs. The classical and most well studied form of MC activation is 
through the high affinity receptor for IgE, FcεRI. This and other forms of MC 
activation will be described below.    16 
 
Figure 3. Different mechanisms of mast cell activation. 
1.5.1  IgE-dependent activation 
MCs express high numbers of the high affinity receptor for IgE (FcεRI) on 
their surface. Cross-linking of FcεRI-bound IgE by an antigen leads to MC 
activation. FcεRI is a tetrameric protein that consists of one α-, one β- and two 
γ-chains. The α-chain is responsible for the high affinity binding of the Fc part 
of IgE and the β- and γ-chains initiate intracellular signaling (Jouvin et al., 
1994;  Hakimi  et  al.,  1990).  The  β-  and  γ-subunits  of  the  receptor  contain 
conserved  cytoplasmic  motifs,  named  immunoreceptor  tyrosine  based 
activation motifs (ITAMs). Upon FcεRI cross-linking, Lyn, a protein tyrosine 
kinase adds phosphate groups to the tyrosine residues in the ITAMs of the 
intracellular β- and γ-subunits. Phosphorylation of the ITAMs allows binding 
and  activation  of  the  protein  tyrosine  kinase  Syk,  which  results  in 
phosphorylation  of  a  number  of  signaling  proteins  finally  leading  to 
degranulation, secretion and de novo synthesis of various mediators (Turner & 
Kinet, 1999). 
1.5.2  IgG-mediated activation 
Antigen-mediated activation of MCs can also be achieved via receptors for IgG 
(FcγRs). Human MCs express the high affinity receptor FcγRI and the low 
affinity  receptor  FcγRII,  whereas  murine  MCs  express  the  low  affinity 
receptors FcγRII and FcγRIII (Okayama et al., 2000; Katz & Lobell, 1995). It 
has been demonstrated that MC degranulation can be triggered by stimulation   17 
of FcγRI or FcγRIII by polyvalent antigen (Daeron et al., 1995). In contrast to 
the  activating  receptors,  FcγRII  contains  an  immunoreceptor  tyrosine  based 
inhibitory motif (ITIM). Crosslinking of FcγRII results in decreased signaling 
of the activating IgE- and IgG-receptors, thereby inhibiting MC degranulation 
and mediator release (Kepley et al., 2000; Daeron & Vivier, 1999).  
1.5.3  Toll-like receptors 
Toll-like  receptors  (TLRs)  are  a  group  of  pattern  recognitions  receptors 
detecting  different  pathogen-associated  ligands.  The  TLR  ligands  can  be 
divided into three categories: proteins, DNA/RNA and lipid based cell-wall 
components. TLRs may facilitate cooperative binding of ligands, thus exhibit a 
broad  recognition  spectrum.  For  example,  TLR  1/2  recognizes  tricylated 
lipoproteins  whereas  TLR  2/6  recognizes  peptidoglycan  from  gram-positive 
bacteria. TLR 2, 3, 4, 6, 8, and 9 are expressed by MCs (Matsushima et al., 
2004;  Takeda  et  al.,  2003).  These  may  directly  recognize  a  number  of 
pathogens,  leading  to  different  MC  responses.  Stimulation  of  TLR  2  with 
peptidoglycan from gram-positive bacteria mediates cytokine production and 
degranulation, whereas stimulation with lipopolysaccharide via TLR 4 induces 
cytokine secretion but no degranulation (Supajatura et al., 2002). Activation of 
MCs via TLR signaling is usually associated with cytokine, leukotriene and 
prostaglandin  production  without  mediating  degranulation  (Marshall  et  al., 
2003; Okumura et al., 2003; Varadaradjalou et al., 2003). This demonstrates 
the importance of MCs in recruitment of inflammatory cells, for example in 
recruiting neutrophils to the local site of activation leading to antimicrobial 
responses and clearance of the invading pathogens.  
1.5.4  Complement mediated activation 
The  complement  system  is  composed  of  serum  proteins  and  cell  surface 
receptors that interact in a number of complex pathways in order to eliminate 
pathogens.  The  complement  system  operates  in  both  innate  and  adaptive 
immunity and can be activated in three different ways; the classical pathway, 
the alternative pathway and the lectin pathway (Sarma & Ward, 2011). Tissue 
damage  and  different  types  of  infections  often  lead  to  activation  of  these 
pathways.  MCs  can  interact  with  the  complement  system  by  expressing 
complement receptor (CR) 3, CR4, C3aR and C5aR (Marshall, 2004). It is well 
established that C3a and C5a are MC-activating agents (Johnson et al., 1975). 
In  mice,  connective  tissue  MCs  (CTMCs),  but  not  mucosal  MCs  (MMCs), 
express CRs and are able to respond to C3a and C5a (Mousli et al., 1994). 
Complement-deficient  mice  are  more  sensitive  and  display  reduced  MC 
activation  after  caecal  ligation  and  puncture  (Prodeus  et  al.,  1997).  Human   18 
MCs also display different expression of receptors depending on surrounding 
environment. C5aR expression has been observed in skin and cardiac MCs, but 
not in MCs from the lungs, uterus and tonsils (Fureder et al., 1995).  
1.5.5  Other mechanisms of activation 
In addition to the mechanisms mentioned above, MCs can be activated by other 
agents such as cytokines, chemokines, neuropeptides, calcium ionophores and 
drugs.  
 
Several  cytokines  and  chemokines  including  IL-1,  IL-3,  IL-8,  granulocyte-
macrophage  colony  stimulating  factor,  macrophage  inflammatory  protein 
(MIP)-1α,  monocyte  chemoattractant  protein  (MCP)-1  and  stem  cell  factor 
(SCF) are able to induce mediator release (Mekori & Metcalfe, 2000; Taylor et 
al., 1995; Alam et al., 1994; Subramanian & Bray, 1987). The small peptide 
endothelin (ET)-1, a 21 amino acid peptide produced by endothelial cells, and 
neuropeptides such as substance P, calcitonin gene related peptide, vasoactive 
intestinal  peptide  (VIP)  and  neurotensin  have  been  shown  to  activate  MCs 
(Bauer & Razin, 2000; Metcalfe et al., 1997). Other MC activators include the 
nucleoside  adenosine  and  the  opiates  morphine  and  codeine  (Mekori  & 
Metcalfe, 2000). Many basic compounds (e.g. compound 48/80, mastoparan 
and  polymers  of  basic  amino  acids)  activate  MCs  directly,  which  leads  to 
degranulation and histamine release (Metcalfe et al., 1997). MC degranulation 
can  also  be  mediated  by  elevating  intracellular  calcium  levels.  Calcium-
mobilizing agents such as calcium ionophore (A23187) and ionomycin both 
have  the  ability  to  mediate  MC  degranulation  (Metcalfe  et  al.,  1997). 
Furthermore, cell-to-cell contact has also been shown to have an impact on MC 
activation. Adhesion of activated T lymphocytes to MCs, via interaction of 
leukocyte  function  associated  antigen  (LFA)-1  and  intracellular  adhesion 
molecule  (ICAM)-1,  induces  mediator  release  and  cytokine  production 
(Bhattacharyya et al., 1998; Inamura et al., 1998). 
1.6  Apoptosis 
MCs are long-lived cells that can regenerate after a degranulation event (Xiang 
et al., 2001; Dvorak et al., 1987; Kobayasi & Asboe-Hansen, 1969). It has 
been  shown  that  the  presence  of  SCF,  the  ligand  for  the  receptor  c-kit,  is 
essential for MC survival both in vitro and in vivo (Iemura et al., 1994). Under 
normal  conditions,  the  number  of  tissue  MCs  is  constant.  Dysregulation of 
apoptosis in MCs can cause accumulation of MCs, which may lead to diseases   19 
such  as  mastocytosis.  Therefore,  induction  of  MC  apoptosis  may  be  an 
approach to treat MC-associated disorders, including asthma.  
1.6.1  Apoptosis activation pathways 
In order to maintain a constant number of cells in the body cell proliferation 
and  programmed  cell  death  occur  in  a  controlled  way.  Apoptosis,  the 
physiological process of programmed cell death, has been preserved during 
evolution and exists in all multicellular organisms. The process of apoptosis 
can be divided into two main signaling pathways, the mitochondrial/intrinsic- 
and the death receptor/extrinsic pathways (figure 4) (Ekoff & Nilsson, 2011). 
The  intrinsic  pathway  is  initiated  by  DNA  damage,  cytotoxic  drugs  and 
cytokine  deprivation.  When  deprived  of  SCF,  MCs  have  been  shown  to 
undergo  apoptosis  via  the  intrinsic  pathway.  Downstream  signaling  of  the 
intrinsic pathway involves the Bcl-2 family of pro-apoptotic proteins (e.g. Bax, 
Bcl-Xs, Bik and Bad) and anti-apoptotic proteins (e.g. Bcl-2, Bcl-XL, Mcl-1 
and A1). Bcl-2 family members control the release of mediators of apoptosis 
triggered by permeabilization of the mitochondrial membrane. The extrinsic 
pathway is triggered by external signals from the environment that mediates 
signaling  by  surface-bound  death  receptors,  e.g.  the  tumor  necrosis  factor 
(TNF)  receptor  family.  Upon  activation,  these  receptors  interact  with 
downstream  molecules  that  activate  a  cascade  of  cysteine  proteases  called 
caspases.  Both  the  intrinsic  and  extrinsic  pathways  involve  intracellular 
activation  of  a  family  of  cysteine  proteases  named  caspases  (Riedl  &  Shi, 
2004). Activation of caspases directly or indirectly induces the morphological 
changes  in  the  process  of  apoptosis  including  cell  shrinking,  chromatin 
condensation, DNA fragmentation and formation of apoptotic bodies (Kerr et 
al., 1972). The apoptotic bodies are efficiently removed by phagocytic cells in 
the local tissue.   20 
 
Figure 4. Intrinsic and extrinsic pathways of apoptosis.  
1.7  Heterogeneity of mast cells 
MCs  can  have  different  phenotypes  and  these  are  dependent  on  different 
factors including the species, environment and even age of the animal. Murine 
MCs are broadly divided into CTMCs and MMCs, summarized in table 1. This 
commonly used nomenclature for murine MCs originates from observations in 
rats, but the same phenotypes were also found in mice (Enerback, 1966). The 
CTMCs are located in the connective tissue of the skin and peritoneum and 
contain  heparin  proteoglycan,  high  amounts  of  histamine  as  well  as  the 
proteases: chymase, tryptase and carboxypeptidase A (CPA). MMCs are found 
at  mucosal  surfaces  such  as  the  lamina  propria  of  the  intestine  and  in  the 
respiratory tract. In contrast to CTMCs, MMCs contain chondroitin sulphate 
proteoglycan and chymase, but do not express tryptase and CPA. Human MCs 
are classified according to their neutral protease content (table 1). The MCT 
phenotype expresses only tryptase, whereas MCTC contain tryptase, chymase, 
CPA and cathepsin G (Irani & Schwartz, 1994). A third, more rare, type of MC 
population, containing only chymase (MCC) has also been reported (Weidner 
& Austen, 1993). However, it should be mentioned that combinations of MCs 
with different phenotypes could be found in murine as well as human tissues. 
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Table 1. Summary of the MC-specific protease and proteoglycan expression in humans and mice. 
Species  Human  Mouse 
MC-subclass  MCT  MCTC  CTMC  MMC 


























Heparin  Chondroitin 
sulfate 
Abbreviations: MC, mast cell; mMCP, mouse mast cell protease; CPA, caboxypeptidase A. Protease name 
indicates expression of respective protease. (–) indicates no expression. 
1.8  Pre-stored mediators in mast cell granules 
Fully differentiated MCs can contain 500-1000 granules filled with pre-stored 
mediators such as proteoglycans, proteases, histamine and cytokines that can 
be released upon activation.  
1.8.1  Proteases 
The MC granules are composed of remarkably high amounts (up to 35%) that 
make up the total protein content of the cell, i.e., proteases that are active at a 
neutral pH (Schwartz et al., 1987a; Schwartz et al., 1987b). The granule-stored 
MCs proteases are divided into chymases, tryptases and CPA (Pejler et al., 
2010). The common feature for all proteases is that they cleave peptide bonds. 
One third of all proteases belong to a large family of proteolytic enzymes with 
a reactive serine (Ser) side chain. These are called serine proteases. Chymase 
and tryptase are serine proteases that hydrolyze bonds within the peptide chain 
of the substrate and are therefore known as endopeptidases. Chymases have 
chymotrypsin-like substrate specificity, i.e., they hydrolyze bonds after large 
hydrophobic  amino  acids  such  as  tyrosine  (Tyr),  tryptophan  (Trp), 
phenylalanine  (Phe)  and  methionine  (Met).  Tryptases  have  trypsin-like 
cleavage specificity and have a preference for cleaving after the basic amino 
acids arginine (Arg) or lysine (Lys). CPA on the other hand is a zinc-dependent 
metalloprotease that cleaves bonds at the ends of peptides and is therefore an 
exopeptidase. Apart from the MC-specific proteases, MCs also express other 
proteases including lysosomal cathepsins, granzymes and cathepsin G (Pejler 
et al., 2007).    22 
1.8.2  Chymase 
Chymases  are  stored  in  the  MC  granules  as  active  monomeric  enzymes  in 
complex with heparin serglycin proteoglycan (Braga et al., 2007; Henningsson 
et al., 2006; Abrink  et al., 2004; Henningsson  et al., 2002). Chymases are 
activated  by  the  proteolytic  removal  of  an  N-terminal  acidic  dipeptide  by 
dipeptidyl peptidase I (DPPI) (Wolters et al., 2001). Within the acidic granules, 
chymase is tightly bound to heparin and this is thought to prevent autolysis by 
the enzymes. Post degranulation, chymase remains in complex with heparin 
proteoglycan,  which  increases  the  enzymatic  activity  and  offers  protection 
from inhibitors outside the cell (Pejler & Sadler, 1999; Pejler & Berg, 1995).  
 
Humans only express one chymase, which belongs to the group of α-chymases 
based on phylogenetic analyses (Chandrasekharan et al., 1996; Caughey et al., 
1991).  In  mice,  MMCs  express  two  β-chymases:  mouse  mast  cell  protease 
(mMCP)-1 and mMCP-2 (Lunderius et al., 2000; Lutzelschwab et al., 1998; 
Huang et al., 1991), although mMCP-2 lacks proteolytic activity (Pemberton et 
al., 2003). CTMCs predominantly express the β-chymase mMCP-4 (Newlands 
et al., 1993) and the α-chymase mMCP-5 (Huang et al., 1991; Reynolds et al., 
1990) (table 1). mMCP-5 is the only α-chymase expressed by murine MCs and 
is the closest homolog to the human chymase based on sequence similarity. 
However, mMCP-5 has elastase-like cleavage specificity and is therefore not 
functionally a chymase (Karlson et al., 2003; Kunori et al., 2002). In contrast, 
mMCP-4 has a similar cleavage specificity and tissue distribution as the human 
chymase (Andersson et al., 2008). This suggests that the functional homolog to 
the human chymase is mMCP-4.   
 
In  vivo  and  in  vitro  studies  have  revealed  that  chymase  is  involved  in  the 
processing  of  a  wide  array  of  proteins  and  peptides.  Most  attention  been 
focused on chymase ability to cleave angiotensin I yielding angiotensin II, a 
peptide involved in vasoconstriction (Urata et al., 1990; Reilly et al., 1982). 
Considering that MCs are widely distributed in the connective tissue it is likely 
that  the  stored  proteases  may  have  a  profound  impact  on  the  extracellular 
matrix (ECM). Indeed, fibronectin, an ECM component, has been shown to be 
a substrate for chymase (Tchougounova & Pejler, 2001; Vartio et al., 1981). 
Further,  it  has  been  demonstrated  that  chymase  induces  apoptosis  in  ECM 
surrounded vascular smooth muscle cells (SMCs) (Leskinen et al., 2001). In 
addition, chymase has the ability to inhibit mitogen-induced SMC proliferation 
(Lazaar  et  al.,  2002).  Chymase  can  also  modulate  the  EMC  composition 
through the release of latent transforming growth factor β-1 (TGF-β1) from the 
matrix,  which  subsequently  enhances  the  production  of  connective  tissue   23 
(Taipale et al., 1995). In contrast, chymase has also been shown to be involved 
in ECM degradation through the activation of matrix metalloproteases and pro-
collagenases. In vivo studies in mMCP-4-deficient mice provided support for 
this notion as  these mice have an increased collagen-deposition in the skin 
(Tchougounova et al., 2005). Chymase has been suggested to be involved in 
regulating the levels of other biological factors including ET-1 (Kido et al., 
1998),  IL-1β  (Mizutani  et  al.,  1991)  and  to  cleave  membrane-bound  SCF 
mediating  its  release  from  the  cell  surface  (de  Paulis  et  al.,  1999).  Taken 
together,  chymase  may  have  pro-inflammatory  properties  through  the 
activation  of  various  substances  as  well  as  anti-inflammatory  by  degrading 
others. 
Chymase knockout mice and in vivo roles 
To date, three chymase knockout mice have been generated: mMCP-1, mMCP-
4 and mMCP-5. mMCP-1 is primarily expressed by intestinal MMCs and mice 
lacking  this  chymase  have  a  delayed  parasite  expulsion  in  the  intestine 
compared to WT mice (Knight et al., 2000). The mMCP-4 knockout mice have 
a deletion in exon 1 of the chymase gene, which results in a complete loss of 
the protein (Tchougounova et al., 2003). These mice have been used in several 
disease models to evaluate the in vivo functions of mMCP-4. For instance, a 
pathological  role  for  mMCP-4  in  experimental  arthritis  has  been  suggested 
since  mMCP-4
-/-  mice  had  decreased  passive  and  active  collagen-induced 
arthritis compared to WT mice (Magnusson et al., 2009). In addition, mMCP-4 
contributes to the development of abdominal aortic aneurism (Sun et al., 2009). 
mMCP-4
-/- mice show increased skin blistering compared to WT mice in a 
model of bullous pemphigoid,  suggesting  a  role  for  mMCP-4  in  ECM  and 
hemidesmosome degradation (Lin et al., 2011). It is well known that MCs are 
important  cells  in  the  innate  defense,  and  a  role  for  mMCP-4  in  reducing 
toxicity of Gila monster and scorpion venom was recently published (Akahoshi 
et al., 2011). mMCP-4 is involved in maintaining homeostasis in the intestinal 
epithelium by regulating barrier properties and migration across the epithelium 
(Groschwitz et al., 2009). mMCP-5 has been shown to contribute to ischemia 
reperfusion-induced injury of skeletal muscle (Abonia et al., 2005). However, 
mMCP-5 knockout mice also lack CPA, which makes it difficult to interpret 
the data. A strategy for overcoming this issue would be to generate genetically 
targeted mice with a mutation in the active site of mMCP-5. 
 
Several  reports  suggest  that  chymase  has  pro-inflammatory  properties.  For 
example,  injection  of  chymase  mediates  accumulation  of  eosinophils  and 
neutrophils  in  vivo  (Terakawa  et  al.,  2005;  He  &  Walls,  1998).  A   24 
polymorphism in the promoter region of the chymase gene has been associated 
with allergic asthma, possibly through regulation of IgE levels (Sharma et al., 
2005).  There  is  also  evidence  suggesting  a  protective  role  for  chymase  in 
severe  asthmatics,  where  the  presence  of  chymase  in  the  small  airways 
correlates with preserved airway function (Balzar et al., 2005). 
1.8.3  Tryptase 
Tryptases are serine proteases with trypsin-like substate specificity active in a 
tetrameric form. Tryptases, like chymases, are stored in complex with serglycin 
proteoglycan within the MC granules as active enzymes (Hallgren et al., 2001; 
Schwartz  &  Bradford,  1986).  Human  MCs  mainly  express  two  types  of 
tryptases: α- and β-type. β-tryptases are the main form of tryptases found in 
MCs and they are the most catalytically active (Marquardt et al., 2002; Huang 
et al., 1999). So far, three different forms of β-tryptases have been identified: 
βI, βII and βIII (Pallaoro et al., 1999). The β-tryptases are very similar to each 
other and βI and βII differ in only one amino acid. The α-tryptases are further 
classified into αI and αII. In contrast to the β-tryptases, αI-tryptases can be 
detected in the circulation in absence of MC degranulation, which suggests that 
they are constitutively secreted (Schwartz et al., 1995). Human tryptases also 
include δ-tryptase and the membrane anchored γ-tryptase form (Hallgren & 
Pejler, 2006). 
 
To date, mice have been found to express four tryptases: mMCP-6, mMCP-7, 
mMCP-11 and mouse transmembrane tryptase (mTMT). mMCP-6, expressed 
by  CTMCs,  is  the  most  similar  to  the  human  β-tryptases  (Hallgren  et  al., 
2000). mMCP-6 and mMCP-7 are not constitutively secreted, but stored in MC 
granules and become exocytosed locally upon degranulation (Ghildyal et al., 
1996). mMCP-11 and mTMT have both been found to be mainly expressed 
during the early stages of MC development (Wong et al., 2004; Wong et al., 
1999).  
 
Like  chymase,  tryptase  has  been  suggested  to  degrade  a  number  of  ECM 
components including fibrinogen (Schwartz et al., 1985), fibronectin (Lohi et 
al., 1992), type VI collagen (Kielty et al., 1993) and to activate pro-MMP-3 
(Gruber et al., 1989). In addition, tryptase has been shown to activate protease-
activated receptor (PAR)-2, which may lead to inflammatory events (Berger et 
al., 2001). There are a number of studies suggesting a role for MC tryptase in 
allergic asthma. Tryptase stimulates the proliferation of SMCs, epithelial cells 
and fibroblasts, which may lead to features associated with asthma including 
AHR and remodeling events of the airways (Gruber et al., 1997; Cairns &   25 
Walls, 1996). Additionally, tryptase can degrade VIP, which, in the lungs, acts 
to relax bronchial smooth muscle (Caughey et al., 1988). Further support for a 
pathological  role  of  tryptase  in  asthma  came  from  studies  where  tryptase 
inhibitors blocked airway inflammation and AHR in allergic sheep (Clark et 
al., 1995). Incubation of isolated human bronchi with tryptase also mediates 
histamine release and promotes a subsequent in vitro bronchial reactivity to 
histamine (Berger et al., 1999).  
1.8.4  Carboxypeptidase A 
CPA is an exopeptidase expressed by MCs and similarly to the other proteases, 
is  stored  as  an  active  enzyme  in  the  granules.  CPA  has  a  high  content  of 
positively  charged  amino  acids  that  enable  binding  to  negatively  charged 
serglycin  proteoglycan  within  the  granules. It  has  been  suggested  that  both 
CPA  and  chymase  remain  in  complex  with  serglycin  proteoglycan  after 
degranulation.  To  date,  only  one  CPA  gene  has  been  identified  and  its 
expression varies among the MC subtypes. In humans, CPA is only expressed 
in the MCTC subtype and in mice CPA is restricted to CTMCs (Reynolds et al., 
1989).  CPA  has  a  preference  for  cleaving  C-terminal  aromatic  or  aliphatic 
residues (Vendrell et al., 2000; Goldstein et al., 1989). Interestingly, substrate 
processing  by  chymase  generates  products  with  a  C-terminal  cleavage 
preference for CPA.  
 
CPA has been shown to be involved in the degradation of ET-1, a 21 amino 
acid  peptide  involved  in  septic  shock  and  the  development  of  high  blood 
pressure (Metz et al., 2006; Metsarinne et al., 2002). In addition, CPA has an 
important  role  in  protecting  against the  snake venom toxin,  sarafotoxin,  by 
preventing its toxicity through C-terminal degradation (Metz et al., 2006).  
1.8.5  Cathepsin G 
Cathepsin G is a serine protease mainly expressed in neutrophils but has also 
been found in MCs. Humans and rodents express one cathepsin  G protein, 
originating from the cathepsin G gene (CTSG) (Schechter et al., 1990). The 
cleavage properties for cathepsin G are broader compared to the other serine 
proteases as it possesses both chymotryptic as well as tryptic activities, i.e., 
cleavage after aromatic and basic amino acids (Polanowska et al., 1998). 
1.8.6  Proteoglycans 
Proteoglycans are ubiquitously expressed and highly abundant proteins with a 
variety of functions. For example, proteoglycans are involved in embryological 
development and functions in most organ systems of the body, including the   26 
immune  system  (Handel  et  al.,  2005;  Iozzo,  2005).  Proteoglycans  are 
composed  of  a  core  protein  with  covalently  linked  long,  unbranched 
glycosaminoglycan (GAG) chains. Proteoglycans can be broadly divided into 
three subgroups i.e. the cell-surface spanning (syndecans and glypicans), the 
ECM  associated  (decorin,  agrin  and  perlecan)  and  the  intracellular 
proteoglycan, serglycin. Serglycin is synthesized by a number of hematopoietic 
cells including MCs, macrophages, lymphocytes, platelets and natural killer 
cells (Pejler et al., 2009).  
 
Serglycin proteoglycan consists of a 17.6 kDa core protein with an extended 
amino acid repeat of serine/glycine (Ser/Gly), where the Ser residues function 
as GAG attachment sites (Ronnberg et al., 2012). The main GAGs found in 
connection  with  serglycin  PGs  are  heparin/heparan  sulfate,  chondroitin  4-
sulfate, chondroitin 6-sulfate and chondroitin sulfate B and E (Table 2) (Kolset 
&  Tveit,  2008).  The  different  combinations  of  GAG  chains  enable  a 
multifaceted biological activity of serglycin proteoglycan.   
Table 2. Serglycin GAG chain expression in granulated cells (adapted from Kolset 2008).  
GAG chain  Cell type 
Heparin/Heparan sulfate   MCs, macrophages 
Chondroitin 4-sulfate   Platelets, monocytes, lymphocytes, natural 
killer cells 
Chondroitin 6-sulfate   Guinea pig platelets 
Chondroitin sulfate E   MCs, macrophages 
Chondroitin sulfate B   Rat basophils 
 
 
Heparin, the most well known GAG and one of the most negatively charged 
molecules in the body, is bound to serglycin in CTMCs (Kolset & Gallagher, 
1990). Because of its highly negatively charged nature heparin can interact 
with  a  number  of  proteins,  including  the  pre-stored  proteases  in  the  MC 
granules. In contrast to CTMCs, MMCs serglycin carries the less negatively 
charged chondroitin sulfate type GAGs (Enerback et al., 1985). Human MCs 
can have both heparin as well as chondroitin sulfate GAG chains bound to the 
serglycin core protein.  
 
Studies in knockout mice have demonstrated that serglycin proteoglycan serve 
as storage matrices for several of the proteases in the MC secretory granules 
(Abrink  et  al.,  2004).  CTMCs  deficient  in  serglycin  proteoglycan  have 
defective staining with cationic dyes and altered storage of a number of granule   27 
compounds  including  mMCP-4,  mMCP-5,  mMCP-6,  CPA  as  well  as  the 
biogenic amines histamine and serotonin (Ringvall et al., 2008; Braga et al., 
2007;  Abrink  et  al.,  2004).  MCs  lacking  glucosaminyl  N-deactylase/N-
sulfotransferase 2 (NDST2), an enzyme involved in the initial step of heparin 
sulphation, have altered secretory granule protease storage due to the lack of 
highly negatively charged heparin (Forsberg et al., 1999; Humphries et al., 
1999).  Thus,  serglycin  proteoglycan  and  negatively  charged  heparin  play  a 
major  role  in  the  storage  of  a  number  of  positively  charged  MC  granule 
proteins. 
 
Upon MC degranulation, serglycin is exocytosed in complex with compounds 
dependent  on  serglycin  for  storage,  as  well  as  with  mediators  that  are 
independent on serglycin for their storage (figure 5) (Schwartz et al., 1981). 
Histamine is dependent on serglycin for storage, but detaches from serglycin 
upon  exocytosis  because  of  the  increase  in  pH  outside  the  acidic  granules. 
However, some proteases remain in complex with serglycin proteoglycan after 
their  release,  which  may  promote  protease  activity  by  enabling  the  close 
proximity of the enzymes with their heparin-binding substrates (Kolset et al., 
2004; Pejler & Sadler, 1999). For example, chymase and CPA remain bound to 
serglycin  proteoglycan  after  degranulation  and  together  may  exert  their 
biological functions at the site of MC activation. In addition to the biological 
functions mediated by serglycin-depedent proteases, serglycin is a ligand for 
CD44,  a  transmembrane  glycoprotein  involved  in  a  number  of  cellular 
processes including regulation of growth, differentiation, motility and survival 
(Toyama-Sorimachi  et  al.,  1995).  Other  biological  roles  of  serglycin  may 
include  protection  of  the  serglycin-interacting  proteins  against  proteolytic 
degradation,  binding  of  inflammatory  compounds  as  regulators  of  immune 
responses  and  delivering  compounds  to  targets  cells.  The  last  notion  was 
suggested  in  cytotoxic  T  lymphocytes,  where  granzyme  B  is  released  in 
complex with serglycin proteoglycan and delivered to the target cells to enable 
subsequent apoptosis (Froelich et al., 1996).  
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Figure 5. Mast cell granule storage and release of serglycin-dependent and 
serglycin-independent mediators. 
 
In  vivo  studies  using  serglycin-deficient  mice  reported  that  Klebisella 
pnemoniae infection was less effectively cleared in the absence of serglycin 
proteoglycan (Niemann et al., 2007). This could possibly be explained by the 
role of serglycin in neutrophil-elastase storage. It has also been shown that 
serglycin
-/- mice show age-related enlargement of lymphoid organs including 
the  spleen,  Payer’s  patches  and  bronchus-associated  lymphoid  tissue 
(Wernersson et al., 2009). This suggests a role for serglycin in maintaining 
homeostasis  of  the  leukocyte  populations,  possibly  through  differentiation 
and/or apoptosis.   
1.8.7  Biogenic amines 
The biogenic amine histamine was discovered in the early 1900’s and has been 
associated with many pathological and physiological conditions. For example, 
histamine  mediates  inflammation,  increases  vascular  permeability,  acts  on 
SMCs, stimulates gastric acid secretion in the gastrointestinal tract and is a 
neurotransmitter  in  the  CNS  (Bachert,  2002).  Histamine  exerts  its  effects 
through  the  histamine  receptors  H1,  H2,  H3  and  H4,  which  belong  to  the 
family  of  G-protein  coupled  receptors  (Haaksma  et  al.,  1990;  Hill,  1990).   29 
Drugs targeting histamine receptors have successfully been in use since the 
1940s. A number of cells including SMCs and endothelial cells express H1 
receptors.  The  main  function  of  H2  receptors  is to  stimulate  the  release  of 
gastric acid. The H3 receptors are primarily expressed in the nervous system. 
Many hematopoietic cells, including MCs, express the H4 receptor. MCs also 
express receptors H1 and H2 receptors, and activation of these has an impact 
on MC mediator release (Lippert et al., 2004).  
1.9  De novo synthesized mediators 
1.9.1  Eicosanoids 
In addition to the pre-stored mediators, MCs also de novo synthesize a number 
of inflammatory mediators from the eicosanoid family. MC activation has been 
shown  to  generate  production  of  prostaglandin  D2  (PGD2)  leukotriene  B4 
(LTB4) and LTC4 (Boyce, 2007).  
 
PGD2, LTB4 and LTC4 are all derived from arachidonic acid released from 
phospholipid  cell  membranes  by  phospholipase  A  (Funk,  2001).  The 
subsequent step in generating PGD2 is conversion of arachidonic acid to an 
intermediate,  PGH2,  by  cyclooxygenase  enzymes  (COXs).  PGH2  is  then 
converted  to  PGD2  by  specific  synthases.  A  number  of  leukocytes  act 
chemotactically to PGD2 and mouse models of allergic airway inflammation 
suggest a pathological role for PGD2 (Honda et al., 2003; Fujitani et al., 2002). 
In  support  of  this  idea,  it  has  been  shown  that  PGD2  mediates 
bronchoconstriction via a Gq-coupled thromboxan receptor (Johnston et al., 
1992). In human asthmatics, increased levels of PGD2 have been observed in 
BAL-fluids (Wenzel et al., 1989). LTB4 and LTC4 are synthesized through a 
pathway  in  which  the  first  step,  arachidonic  acid  to  LTA4  conversion,  is 
catalyzed by the enzyme 5-lioxygenase (5-LO) (Malaviya & Jakschik, 1993). 
LTA4 can be then be converted to either LTB4 (by LTA4-hydrolase) or LTC4 
(by LTC4 synthase) (Lam et al., 1994; Evans et al., 1985). Both LTB4 and 
LTC4 are released and actively transported from the cell. Extracellularly, LTC4 
is converted to LTD4 and subsequently LTE4. Collectively, LTC4, LTD4 and 
LTE4 are referred to as cysteinyl leukotrienes, where LTE4 is the least reactive 
but most stable of the three (Boyce, 2007). Like PGD2, leukotrienes mediate 
their biological effects via G-protein coupled receptors. Leukotrienes exert pro-
inflammatory  properties  acting  as  a  chemoattractants  on  a  number  of 
inflammatory cells, including MC progenitors (Weller et al., 2005). Similarly 
to  PGD2,  allergen-challenged  asthmatics  have  increased  levels  of  cysteinyl 
leukotrinenes in their BAL-fluid and cysteinyl leukotrienes mediate contraction   30 
of the bronchi as well as pulmonary vascular smooth muscle (Wenzel et al., 
1990; Hanna et al., 1981; Dahlen et al., 1980).  
1.9.2  Cytokines and chemokines 
MCs are known to produce a number of  pro-inflammatory as well as anti-
inflammatory cytokines. Different routes of MC activation releases cytokines 
including  IL-1β,  IL-3,  IL-4,  IL-5,  IL-6,  IL-9,  IL-10,  IL-13,  IL-33,  basic 
fibroblast growth factor (bFGF)-2, granulocyte-macrophage colony-stimulating 
factor  (GM-CSF)  and  TGF-β1  (Ishizuka  et  al.,  1999;  Kanbe  et  al.,  1999a; 
Kanbe et al., 1999b; Qu et al., 1998; Okayama et al., 1995; Razin et al., 1984). 
The majority of the secreted cytokines are newly synthesized, however, MCs 
are also capable of pre-storing cytokines in their granules, which was initially 
shown with tumor necrosis factor α (TNFα) (Walsh et al., 1991; Young et al., 
1987). There is also evidence that MCs can store IL-4 (Gibbs et al., 1997), 
SCF (Zhang et al., 1998), TGFβ (Lindstedt et al., 2001) and nerve growth 
factor (Leon et al., 1994) in their secretory granules. Chemokines belong to a 
cytokine family of chemotactic proteins that are involved in trafficking and 
recirculation of various immune cells.  They can also stimulate many immune 
cells including T cells, eosinophils and monocytes to produce cytokines.  MCs 
secrete the chemokine IL-8 that acts to recruit neutrophils (Kasahara et al., 
1998).  In  addition,  MCs  also  express  MCP-1  and  RANTES  that  are 
monocyte/macrophages chemoattractants (Ono et al., 2003).  
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2  Present investigations 
2.1  Aims of the present studies 
The general aim has been to evaluate the role of serglycin proteoglycan and 
MC proteases in allergic disease and apoptosis. Specific attention was paid to 
the MC chymase, mMCP-4, and its role in allergic airway inflammation. More 
specifically, this thesis aims to: 
 
•  Investigate  the  role  of  mMCP-4  in  ovalbumin  (OVA)-induced  allergic 
airway inflammation (paper I). 
 
•  Investigate  the  role  of  mMCP-4  and  evaluate  mechanisms  by  which 
mMCP-4  regulates  airway  inflammation  induced  by  house  dust  mite 
(HDM)-extract (paper II). 
 
•  Determine  how  MC  proteases  regulate  levels  of  the  asthma-related 
cytokine IL-13 in vitro (paper III). 
 
•  Study  the  impact  of  serglycin  proteoglycan-associated  proteases  on 
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2.2  Results and Discussion 
In this section, the main results from papers I – IV are summarized.  
2.2.1  Paper I: Mouse mast cell protease 4 is the major chymase in murine 
airways and has a protective role in allergic airway inflammation. 
 
MCs are known to be key effector cells in IgE-associated immune responses 
e.g. allergy and asthma. Activation of MCs by cross-linking of IgE bound to 
FcεRI receptors leads to the release of large amounts of newly synthesized and 
granule-stored pro-inflammatory mediators. These include histamine, serglycin 
proteoglycan and proteases such as chymases, tryptases and CPA.  
 
The contribution of chymase in the context of allergic asthma is not completely 
understood. Therefore, defining the role of chymase is important for a deeper 
understanding  of  the  molecular  mechanisms  of  how  MCs  contribute  to  the 
disease.  In  paper  I,  the  main  aim  was  to  define  the  role  of  MC  chymase 
(mMCP-4) in a murine model of allergic airway inflammation.  
 
The selection of a model for studying MCs in allergic airway inflammation is 
not trivial. Strong immunization protocols, including adjuvants, may diminish 
the role of MCs. Conversely, weak immunization protocols,  using only the 
allergen  for  sensitization  and  provocation,  have  been  shown  to  reveal  a 
significant role for MCs in the development of allergic airway inflammation 
(Taube  et  al.,  2004;  Kobayashi  et  al.,  2000;  Williams  &  Galli,  2000). 
Therefore, we decided to use an acute model of allergic airway inflammation 
with immunizations/provocations with the antigen alone. This model involved 
seven intra peritoneal (i.p.) immunizations (sensitization) with OVA on day 1, 
3, 6, 8, 10, 13 and 15 followed by three intra nasal (i.n.) challenges with OVA 
on day 31, 34 and 36. 
 
Airway  inflammation  is  a  feature  of  asthma,  and  this  is  characterized  by 
infiltration of eosinophils and other inflammatory cells to the airways. In both 
WT  and  mMCP-4
-/-  mice,  OVA  sensitization  and  challenge  induced  a 
markedly larger number of inflammatory cells in the BAL fluid. Differential 
count of BAL cells showed an increase mainly in the number of eosinophils, 
but also the number of lymphocytes and neutrophils. However, there were no 
significant differences when comparing BAL cells of WT and mMCP-4
-/- mice. 
OVA-induced lung tissue inflammation was seen in both WT and mMCP-4
-/- 
mice.  Interestingly,  lung  tissue  inflammation  was  more  pronounced  in  the   33 
absence of mMCP-4. These data suggests a role for mMCP-4 in regulating 
tissue inflammation. 
 
Lung function analyses revealed that OVA sensitized/challenged mMCP-4
-/- 
mice  exhibited  significantly  higher  average  lung  resistance  (RL)  than 
corresponding  WT  mice  in  response  to  i.v.  methacholine.  Neither  OVA 
sensitized/challenged WT mice, nor OVA sensitized control groups showed 
any AHR. The absence of AHR in OVA sensitized/challenged WT mice could 
possibly be explained by the use of the known low-responder C57BL/6J stain 
and  weak  immunization  protocol.  These  results  show  that  the  presence  of 
mMCP-4 protects from development of AHR in this model of allergic airway 
inflammation. 
 
Genetic  inactivation  of  mMCP-4  leads  to  a  complete  loss  of  chymotryptic 
activity  in  the  peritoneum  and  ear  tissue  (Tchougounova  et  al.,  2003). 
However, there are several chymases expressed in mice. To further investigate 
the  effect  of  mMCP-4  on  chymotryptic  activity  in  lung  tissue  we  stained 
sections  with  the  chloroacetate  esterase  assay.  As  shown  by  intense  red 
staining of the MCs, chymotrypsin-like activity was detected in the lungs from 
WT mice compared to weak staining found in mMCP-4
-/- mice. This finding 
shows that mMCP-4 is the major enzyme with chymotrypsin-like activity in 
murine lungs.  
 
Airway inflammation  in  asthmatics  may be accompanied by  hyperplasia  or 
hypertrophy  of  the  smooth  muscle  layer  in  the  lungs  (Cockcroft  &  Davis, 
2006). Chymase has previously been shown to regulate apoptosis in ASM by a 
secondary effect of fibronectin degradation (Leskinen et al., 2003). In support 
of this notion, we detected fibronectin fragments in the lungs from WT, but not 
in  mMCP-4
-/-  mice.  Additionally,  chymase  has  been  shown  to  degrade  the 
pericelullar  matrix  of  ASM  and  inhibit  mitogen-induced  ASM  proliferation 
(Lazaar et al., 2002). In our model, OVA sensitization/challenge induced an 
increased ASM thickening in mMCP-4
-/- mice but not in the corresponding WT 
mice,  suggesting  that  mMCP-4  is  involved  in  the  regulation  of  ASM 
hyperplasia/hypertrophy.  We  therefore  investigated  whether  mMCP-4  could 
cleave SMC mitogens. In vitro studies showed that mMCP-4 could cleave both 
platelet derived growth factor (PDGF)-BB and FGF. A possible explanation for 
the protective role of mMCP-4 in allergic asthma could be via the degradation 
of  SMC  mitogens  or  ECM  components.  However,  the  broad  substrate 
specificity for mMCP-4 suggests that other protective mechanisms may also be 
involved.    34 
 
To summarize, this study shows that the presence of mMCP-4 has an effect on 
airway reactivity to methacholine, tissue inflammation and ASM thickening in 
this model of allergic airway inflammation.  
 
Summary (Paper I) 
￘  Presence of mMCP-4 protected from the development of AHR and tissue 
inflammation in this OVA-induced model of allergic airway inflammation. 
￘  As  shown  by  chloroacetate  esterase  staining,  mMCP-4  was  the  major 
chymotryptic enzyme in the murine airway MCs. 




2.2.2  Paper II: Mast cell chymase modulates IL-33 levels and controls allergic 
sensitization in dust-mite induced airway inflammation. 
 
In paper I, we showed a protective role of the MC chymase, mMCP-4, in an 
acute model of allergic airway inflammation. However, the mechanism for this 
finding was not completely clear. Together with the search for the protective 
properties of mMCP-4 demonstrated in paper I, the objective of this study was 
also to investigate the role of mMCP-4 in a more chronic and physiologically 
relevant model of airway inflammation. HDMs are one of the most prominent 
airborne allergens causing asthma in humans. In murine models, repeated i.n. 
exposure  of  HDM  generates  features  of  airway  inflammation  similar  to  its 
human  counterpart  (Fattouh  et  al.,  2005).  It  has  been  shown  that  after 
continuous exposure to OVA, mice develop tolerance to the allergen rather 
than  show  features  of  chronic  airway  inflammation.  On  the  other  hand, 
repeated  exposure  of  HDM  induces  a  robust  eosinophilic  pulmonary 
inflammation,  production  of  IgE-antibodies  as  well  as  airway  reactivity  to 
methacholine. Based on this information, we decided to use a HDM-induced 
model of pulmonary inflammation. 
 
I.n. exposure of HDM-extract twice weekly for three weeks induced BAL and 
lung tissue eosinophilia, and this was significantly higher in mMCP-4
-/- mice. 
The inflammatory response was accompanied by a significantly higher RL to 
inhaled methacholine in these mice. Increased AHR may correlate with ASM 
hypertrophy  and  an  increase  in  ASM  thickness  was  found  in  HDM-treated 
mMCP-4
-/- mice. In agreement with our pervious data (paper I), the presence of 
mMCP-4  limited  airway  inflammation,  AHR  and  ASM  thickening.  In  this   35 
model mMCP-4 also contributed to the sensitization process, shown by the 
significantly  higher  IgE-levels  in  HDM-treated  mMCP-4
-/-  compared  to  the 
corresponding  WT  mice.  In  vitro  re-stimulation  of  splenocytes  with  HDM-
extract demonstrated an increase in the IL-13 and IL-17A cytokine production, 
and this increase was more pronounced in mMCP-4
-/- mice.  
 
HDM allergens can induce MC activation and degranulation in the absence of 
allergen-specific  antibodies  (Machado  et  al.,  1996).  In  agreement  with 
previous reports, we showed that peritoneal MCs degranulate and release both 
histamine and β-hexosaminidase in response to HDM-extract. We also found 
that  chymase  activity  was  detected  in  cultures  of  HDM-stimulated  WT 
peritoneal cell-derived mast cells (PCMCs), yet almost absent in mMCP-4
-/- 
PCMCs. This shows that mMCP-4 accounts for almost all chymase activity in 
peritoneal  MCs.  In  murine  lungs,  the  presence  of  mMCP-4  is  essential  for 
detection of chymotrypsin-like activity using the chloroacetate esterase assay 
(paper I). Together, these findings suggest that mMCP-4 is secreted in murine 
lungs post HDM-challenge. 
 
Production of TH2 cytokines is a characteristic of allergic airway responses. As 
described  above,  i.n.  exposure  of  HDM-extract  induced  recruitment  of 
inflammatory  cells  to  the  airways  of  the  treated  groups,  which  may  be 
accompanied by increased levels of inflammatory mediators in the lung tissue. 
Therefore,  we  measured  the  levels  of  different  TH2  cytokines  in  lung 
homogenates. We did not detect any significant increases in the levels of TH2 
cytokines IL-5, IL-13 and thymic stromal lymphopoietin (TSLP). In contrast, 
HDM-treated mMCP-4
-/- mice exhibited increased levels of IL-33 in the lungs, 
compared  with  corresponding  WT  mice  as  well  as  mMCP-4
-/-  controls. 
Chymase has relatively broad cleavage specificity and previous studies have 
shown that chymase can cleave a number of inflammatory mediators, ECM 
components, lipoproteins and angiotensin I. Our in vitro studies revealed that 
WT  PCMCs  degrade  IL-33  more  effectively  than  mMCP-4
-/-  PCMCs. 
Additionally, inhibitory studies showed that IL-33 degradation by PCMCs is 
blocked by Pefabloc SC, a serine protease inhibitor. These data demonstrate 
that  mMCP-4,  together  with  other  serine  proteases,  contribute  to  IL-33 
degradation in vitro.  
 
In  conclusion,  we  propose  that  the  local  secretion  of  mMCP-4  by  MCs  in 
response to HDM allergens dampens allergic airway inflammation, possibly 
through the effects on IL-33. Our results indicate that different MC mediators 
may  have  inflammatory  or  regulatory  functions  at  sites  of  allergic   36 
inflammation. This may be of clinical interest, in particular for approaches to 
target specific MC mediators in allergic asthma. 
  
Summary (Paper II) 
￘  Lack  of  mMCP-4  resulted  in  a  higher  RL  to  inhaled  methacholine  in  a 
HDM-model of asthma. 
￘  Recruitment of inflammatory cells to BAL and lung tissue was enhanced in 
HDM-treated mMCP-4
-/- mice. 
￘  Lung tissue levels of IL-33 were enhanced in mMCP-4
-/- mice but not in 
WT mice exposed to HDM-extract.  
￘  In  vitro,  WT  PCMCs  degraded  IL-33  more  efficiently  than  mMCP-4
-/- 
PCMCs and this degradation was blocked by a serine protease inhibitor.  
 
2.2.3  Paper  III:  Mast  cells  limit  extracellular  levels  of  IL-13  via  a  serglycin 
proteoglycan-serine protease axis. 
 
Some cells release pre-stored mediators in response to various stimuli thereby 
exerting their biological functions. MCs store large amounts of active proteases 
in their secretory granules. Studies in knockout mice have demonstrated that 
serglycin  proteoglycan  is  implicated  in  the  storage  of  several  of  the  MC 
proteases, e.g. mMCP-4, mMCP-5, mMCP-6 and CPA. Chymase, tryptase and 
CPA belong to the abundant proteases stored in the MC granules, and may 
therefore  have  a  large  impact  on  many  physiological  and  pathological 
processes upon degranulation.  
 
The  objective  of  this  study  was  to  investigate  whether  MCs  deficient  in 
serglycin-proteoglycan  or  in  various  serglycin-dependent  proteases  could 
regulate local levels of IL-13. Peritoneal cells from WT and different knockout 
strains were cultured in vitro in order to generate homogenous populations of 
MCs (Malbec et al., 2007). Exogenous IL-13 was added to the cultures. 
 
After activation with calcium ionophore, WT MCs reduced the levels of IL-13 
in  the  cell  supernatant  whereas  serglycin
-/-  MCs  totally  lacked  this  ability. 
Inhibitory  studies  demonstrated  that  proteolytic  degradation  of  IL-13  was 
completely blocked by a serine protease inhibitor. Further inhibitory studies 
showed  that  degradation  of  IL-13  was  dependent  on  the  interaction  of  the 
serine proteases with heparin, since the heparin antagonist protamine blocked 
the proteolytic activities of the activated MCs. Additional studies with PCMCs 
deficient  in  various  proteases  revealed  that  CPA
-/-  PCMCs  were  unable  to   37 
degrade IL-13. However, cells expressing an inactive form of CPA exhibited 
IL-13  degradation  similar  to  WT  cells.  In  addition,  studies  using  a 
metalloprotease inhibitor had no effect on the proteolytic degradation of IL-13.  
The exact mechanism behind these findings remains intriguing. 
 
The results in this study show that proteolytic degradation of IL-13 by PCMCs 
is mediated by a serine protease, dependent on serglycin proteoglycan for its 
storage. Although MCs are mainly considered as effector cells during allergic 
responses, the present study provides an indication that serglycin-dependent 
serine proteases in MCs may also have immunomodulatory functions in vivo, 
down-regulating inflammatory responses through degradation of inflammatory 
cytokines. 
 
Summary (paper III) 
￘  WT PCMCs effectively reduced levels of exogenously added IL-13 in vitro 
after degranulation. 
￘  Degradation of IL-13 by MCs was dependent on the presence of serglycin 
proteoglycan and CPA. 
￘  Blocking of serine protease activity inhibited proteolytic degradation of IL-
13. 
 
2.2.4  Paper IV: A role for sergycin proteoglycan in mast cell apoptosis induced 
by a secretory granule-mediated pathway. 
 
In this study we investigated the role of serglycin proteoglycan in cell death 
induced  by  H-Leu-Leu-OMe  (LLME),  a  lysosomotropic  agent  shown  to 
mediate apoptosis in a number of hematopoietic cells. Lysosomal membrane 
permeabilization  often  leads  to  apoptosis  through  the  release  of  lysosomal 
proteases.  This  is  followed  by  proteolytic  activation  of  pro-apoptotic 
compounds as well as degradation of anti-apoptotic molecules. MC granules 
are similar to lysosomes in terms of membrane composition but also in their 
storeage of large amounts of proteases. Therefore we hypothesized that LLME-
treatment  of  MCs  may  have  an  impact  on  cell  death  mediated  via  a 
lysosome/granule components-pathway.  
 
In order to evaluate how serglycin proteoglycan affects cell death in MCs we 
cultured bone marrow-derived mast cells (BMMCs) in vitro. The fractions of 
apoptotic and necrotic/late-stage apoptotic cells were determined using staining 
for annexin V and propidium iodide (PI) respectively. After a 4h incubation   38 
with  LLME,  at  different  concentrations,  we  showed  that  serglycin-deficient 
BMMCs  were  more  resistant  to  apoptosis  compared  to  WT  BMMCs.  This 
suggests that serglycin proteoglycan is involved in apoptosis, mediated via a 
secretory-granule pathway.  
 
Acridine orange, a weak basic dye, is taken up by living cells and accumulates 
in  acidic  compartments  such  as  lysosomes  and  secretory  granules.  High 
concentrations of acridine orange give rise to an orange fluorescence, whereas 
low  concentrations  yield  a  green  fluorescent  signal.  To  evaluate  granule 
damage by LLME, WT and serglycin
-/- BMMCs were stained with acridine 
orange  and  their  fluorescence  was  analyzed.  WT  BMMCs  exhibited  a 
reduction in acridine orange staining intensity and cellular decomposition after 
LLME treatment,  whereas serglycin
-/-  BMMCs  showed a markedly reduced 
susceptibility to LLME treatment. Using a substrate for cysteine cathepsins, we 
detected protease activity in cytosolic extracts from WT BMMCs after LLME-
treatment, but the cleaving activity was minimal in LLME-treated serglycin
-/- 
BMMCs.  Inhibitory  studies  revealed  that  cysteine  cathepsins  and  serine 
proteases were released into the cytosol. These data demonstrate that apoptosis 
induced by LLME mediates the release of proteases into the cytosol and that 
presence  of  serglycin  is  essential  for  the  proteolytic  activity.  Activation  of 
caspase-3 plays a central role in apoptosis mediated by a number of pathways. 
Therefore, caspase-3 activity was analyzed in WT and serglycin
-/- BMMCs in 
response to LLME. The WT BMMCs showed a substantial increase in caspase-
3  activity,  whereas  activity  in  serglycin
-/-  BMMCs  was  at  base-line  levels 
except for a slight increase in activity at the highest concentrations of LLME.  
 
MC  proteases  mMCP-4,  mMCP-5,  mMCP-6  and  CPA  are  dependent  on 
serglycin proteoglycan for storage in the secretory granules. To evaluate if the 
separate  proteases  could  be  involved  in  apoptosis  mediated  by  secretory 
granule permeabilization we used knockout mice deficient in either of these 
proteases to generate BMMCs. These studies revealed that BMMCs deficient 
in  mMCP-4,  mMCP-6  or  CPA  were  slightly  less  susceptible  to  apoptosis. 
Therefore, these proteases may account for some of the serglycin-dependent 
resistance to LLME-induced apoptosis.  
 
This  study  uncovers  the  importance  of  serglycin  proteoglycan  in  a 
lysosome/secretory granule pathway of apoptosis.  
 
 
   39 
Summary (paper IV) 
￘  Compared  to  WT  BMMCs,  serglycin
-/-  BMMCs  were  more  resistant  to 
apoptosis mediated by LLME and exhibited reduced protease activity in the 
cytosol as well as caspase-3 activity.  
￘  As  shown  by  inhibitory  studies,  apoptosis  induced  by  secretory  granule 
damage was dependent on cysteine cathepsins. 
￘  LLME-mediated apoptosis was slightly reduced in BMMCs deficient for 
the serglycin-dependent proteases mMCP-4, mMCP-6 or CPA, indicating 
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3  Concluding remarks and future 
perspectives 
MCs are key effector cells in allergic reactions but also important players in the 
innate defense against various pathogens. The striking feature of MCs are their 
secretory  granules  densely  packed  with  various  pre-formed  mediators 
including proteases and proteoglycans. Large amounts of fully active proteases 
are  released  upon  degranulation  and  these  may  therefore  have  a  profound 
influence  in  different  settings.  The  contribution  of  specific  MC  proteases 
remains to be clarified further. Therefore, the use of different knockout strains 
can  contribute  to  a  deeper  understanding  of  the  in  vivo  roles  of  specific 
proteases.  
 
The first two studies of this thesis have focused on the biological role of MC 
chymase in allergic asthma. Animal models for human asthma can provide a 
useful understanding of the molecular mechanisms behind the disease. In the 
different murine models selected we used OVA or HDM-extract as allergens. 
Our models mimic several of the features in human allergic asthma, such as 
AHR, recruitment of eosinophils to the lungs and production of IgE antibodies. 
We  have  presented  evidence  that  mMCP-4,  the  functional  homolog  to  the 
human chymase, has a protective role in the disease, preventing eosinophilia 
and  AHR,  and  this  could  possibly  be  explained  by  the  defective  ability  to 
degrade  the  pro-inflammatory  cytokine  IL-33.  Taken  together,  our  findings 
suggest that MCs can possess both detrimental as well as protective properties 
in  the  development  of  allergic  airway  inflammation.  We  will  continue  to 
investigate the mechanism behind the increased IgE levels in mMCP-4
-/- mice 
after HDM-treatment. It will be of particular interest to study whether chymase 
affects dendritic cell activation. Since our data provides information that the 
chymase has a protective role in the development of airway inflammation, it 
would also be of great interest to study the effects of chymase inhibitors in   42 
these  models.  Today,  guidelines  for  treatment  of  asthma  mainly  involve 
inhaled  glucocorticoids  and  β2-adrenoreceptor  agonists.  Selective  protease 
inhibitors have been discussed as therapeutic applications. Chymase inhibitors 
are effective in reducing abdominal aortic aneurism and myocardial infarction 
(Tsunemi et al., 2004; Hoshino et al., 2003; Jin et al., 2003). However, it is 
important  to  keep  in  mind  that  the  MC  proteases  may  have  different  roles 
depending  on  the  physiological  context  and  the  aim  is  not  to  profoundly 
interfere with their beneficial functions. From the in vitro studies presented in 
this  thesis  MCs  degrade  IL-13,  and  this  is  dependent  on  serglycin 
proteoglycan. These data indicate a role for serglycin-dependent proteases in 
controlling extracellular levels of pro-inflammatory cytokines. We will look 
further  into  whether  this  is  a  specific/selective  degradation  using  other 
cytokines  and  chemokines  with  pro-  and  anti-inflammatory  properties.  In 
summary,  unraveling  the  underlying  mechanisms  for  the  protective  role  of 
mMCP-4 in allergic airway inflammation will hopefully provide new insights 
into the roles of MCs and chymase in asthma.  
 
The intracellular proteoglycan serglycin is expressed by many hematopoietic 
immune  cells.  In  MCs,  serglycin  proteoglycan  is  essential  for  the  proper 
storage of a number of granule-stored mediators including chymase, tryptase 
and  CPA.  The  in  vitro  studies  presented  in  this  thesis  suggest  a  role  for 
serglycin  proteoglycan  in  MC  apoptosis  mediated  by  secretory  granule 
damage.  Since  serglycin  proteoglycan  is  expressed  by  a  number  of  other 
hematopoietc  cell  types  it  is  of  interest  to  study  whether  serglycin  affects 
apoptosis in for example macrophages, neutrophils or cytotoxic T cells.  
 
The  studies  included  in  this  thesis  will  hopefully  provide  a  deeper 
understanding in some of the roles MCs and MC mediators play in allergic 
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4  Populärvetenskaplig sammanfattning  
Mastcellen är ofta en av de första immuncellerna som kommer i kontakt med 
de bakterier, virus och allergener vår kropp utsätts för dagligen. De finns rikligt 
representerade i vår hud och slemhinnor, såsom lungor och mag-tarmkanalen. 
Mastcellen innehåller en stor mängd sekretoriska vesiklar s.k. granula som vid 
aktivering  kan  frisättas  och  innehållet,  bl.a.  histamin,  proteaser  och 
proteoglykaner utsöndras i den närliggande miljön.  Effekterna vid mastcells-
aktivering  kan  vara  goda  då  dess  skyddande  egenskaper  kan  eliminera 
angripande parasiter eller neutralisera toxiner från ormbett, men även skadliga i 
samband med symptomen som uppstår vid allergiska reaktioner.  
 
Proteaser  är  en  typ  av  proteiner  vars  funktion  är  att  klyva  olika  typer  av 
målmolekyler. Stora mängder, upp emot en tredjedel, av innehållet i granula 
utgörs  av  proteaserna  kymas,  tryptas  och  karboxypeptidas  A.  För  att 
proteaserna  ska  kunna  lagras  i  granula  behövs  en  speciell  proteoglykan, 
serglycin  som  består  av  en  proteinkärna  med  flera  negativt  laddade 
kolhydratkedjor  inbundna.  Vid  avsaknad  av  serglycin  proteoglykan  kan 
mastcellen i princip inte lagra några proteaser i sina granula. 
 
För att undersöka vilken roll mastcellens kymas har vid allergisk astma har vi 
använt  oss  av  experimentella  musmodeller  och  genetiskt  modifierade  möss 
som med hjälp av knockoutteknologi saknar ett av mössens kymas, mMCP-4. 
Genom att exponera mössen för allergener från ägg (artikel I) eller kvalster 
(artikel II) efterliknas de symptom som man ser hos människor med allergisk 
astma.  
 
Genom  att  använda  allergener  från  ägg  i  en  experimentell  modell  för  akut 
luftvägsinflammation (artikel I) kunde vi visa att närvaro av kymas hade en 
skyddande  roll  då  luftvägsreaktiviteten  och  inflammationsgraden  i  lungorna   44 
var  högre  i  mössen  som  saknade  kymas.    Vidare  undersökning  av  den 
underliggande mekanismen visade att kymas kan ha en hämmande effekt på 
den glatta muskulaturen kring bronkerna.  
 
Sökandet efter mekanismen bakom fyndet med kymas skyddande egenskaper 
studerades vidare i en mer kronisk experimentell modell för allergisk astma där 
mössen  exponerades  för  kvalsterextrakt  intranasalt  (artikel  II).  Kvalster  är 
luftburna  allergener  som  är  välkända  för  att  ge  upphov  till  astma  hos 
människor  och  är  därmed  ett  mer  relevant  allergen  ur  ett  fysiologiskt 
perspektiv.  Även  i  denna  modell  hade  närvaro  av  kymas  en  skyddande 
funktion  på  luftvägreaktiviteten,  inflammationen  i  lungan  samt  den  glatta 
muskulaturen kring bronkerna. För att förstå mekanismen bakom dessa fynd 
analyserade  vi  proteiner  i  lungvävnaden.  Vi  fann  att  nivåerna  av  ett 
immunologiskt  signalprotein,  interleukin  33,  var  kraftigt  förhöjda  i  mössen 
som saknade kymas. Genom vidare studier kunde vi visa att kymas är ett av 
proteaserna  inuti  mastceller  som  bidrar  till  att  klyva  sönder  interleukin  33. 
Andra experimentella studier har visat att närvaron av interleukin 33 bidrar till 
ökad  luftvägsreaktivitet  och  inflammation  i  luftvägarna  hos  möss. 
Nedbrytningen av interleukin 33 av kymas skulle kunna vara en förklaring till 
de skyddande egenskaper vi fann i våra experimentella modeller av allergisk 
astma. Det vi visat med våra studier är att trots att det är känt att mastcellen 
bidrar  till  patogenesen  vid  allergisk  astma  kan  den  även  frisätta  specifika 
ämnen med skyddande egenskaper.  
 
Mastcellens  lagrade  proteaser  har  förmågan  att  klyva  olika  typer  av 
inflammatoriska proteiner, t.ex. interleukiner. Vi ville i artikel III undersöka 
förmågan hos mastceller, som saknar proteoglykanen serglycin, att klyva ett 
interleukin  som  är  viktigt  vid  utvecklandet  av  allergier  och  astma.  Dessa 
studier  gjordes  på  odlade  mastceller  som  ursprungligen  togs  från  genetiskt 
modifierade möss. Mastcellerna aktiverades i närvaro av interleukin 13 och 
nivåerna  efter  aktivering  jämfördes  med  nivåerna  från  vild-typs  (intakta) 
mastceller. Frånvaron av proteaser i granula gör att mastcellerna inte kan bryta 
ner interleukin 13. Genom att tillsätta enzymhämmare, som kan blockera olika 
typer av proteaser, kunde vi visa att klyvningen av interleukin 13 är beroende 
av s.k. serinproteaser.  
 
I avhandlingens sista studie (artikel IV) undersökte vi hur odlade mastceller 
som  saknar  proteoglykanen  serglycin  påverkas  vid  inducerad  celldöd  s.k. 
apoptos.  Ett  ämne  som  tränger  in  i  cellerna  och  väl  inuti  permeabiliserar 
vesiklar, såsom sekretoriska granula och lysosomer, användes för att inducera   45 
apoptos. I denna studie kunde vi visa att serglycin proteoglykan är involverad i 
programmerad  celldöd  som  inducerats  genom  intracellulär  frisättning  av 
reaktiva ämnen från granula och lysosomer.   
 
Sammanfattning: 
•  Mastcellen  är  känd  för  att  bidra  till  astma,  men  vi  har  visat  att  ett  av  
proteaserna  i  dess  granula,  kymas,  har  skyddande  egenskaper  vid 
uppkomsten av allergisk luftvägsinflammation.  
•  Speciella  proteaser  som  frisätts  vid  aktivering  av  mastcellen  kan  klyva 
sönder inflammatoriska signalproteiner. 
•  Mastceller  som  saknar  proteoglykanen  serglycin  är  mindre  benägna  att 
genomgå apoptos om den induceras via permeabilisering av intracellulära 
vesiklar.    
 
Våra upptäckter kan förhoppningsvis bidra till bättre förståelse för mastcellens 
roll  vid  allergisk  astma.  Att  förstå  mekanismer  som  reglerar 
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